Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response

A Cluster-Randomized Study to Examine National Characteristics and Outcome Measures of GERD Patients Utilizing the PPI Acid Suppression Symptom (PASS) Test for Response [EncomPASS].

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00392002

Enrollment

2000

Registered

2006-10-25

Start date

2005-10-31

Completion date

2007-05-31

Last updated

2008-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal Reflux

Keywords

GERD

Brief summary

To characterize the burden of disease in GERD patients of prescription therapy'

Interventions

DRUGEsomeprazole

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Signed informed consent, 18 years or older, diagnosis of GERD

Exclusion criteria

* Peptic ulcer disease, upper gastrointestinal surgery, malignancy

Design outcomes

Primary

Measure	Time frame
To compare the improvement in burden of overall GERD symptoms after 4 weeks of treatment with Esomeprazole verses maintenance of current therapy in subjects with persistent GERD symptoms.	—

Secondary

Measure	Time frame
To examine the relationship of the severity and frequency of GERD symptoms to treatment, at national, and regional levels.	—

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026